Rxivist logo

Comparative Efficacy and Safety of Pharmacological Managements for Hospitalized COVID-19 Patients: Protocol for Systematic Review and Trade-Off Network Meta-Analysis.

By Min Seo Kim, Won Jun Kim, Min Ho An

Posted 22 May 2020
medRxiv DOI: 10.1101/2020.05.18.20103697

Coronavirus-Disease 2019 (COVID-19) is the clinical disease caused by the SARS-CoV-2 virus, the infectious agent causing the ongoing pandemic that has impacted the lives of hundreds of millions of people in almost every nation worldwide. It is a potentially fatal disease to many vulnerable patients including the elderly and those with chronic illnesses; but because this virus is a novel one, there are no firmly established treatment protocols. Many treatment methods are being investigated worldwide, and scientific conclusions drawn from these endeavors are crucial for healthcare professionals in combating this disease. In this network meta-analysis, we focus specifically on the pharmacologic agents that have been investigated for the treatment of COVID-19 and aim to produce a comprehensive picture of the evidence from current data in order to produce relevant insights on the comparative efficacy and safety profiles of various pharmacologic agents against COVID-19.

Download data

  • Downloaded 399 times
  • Download rankings, all-time:
    • Site-wide: 77,159
    • In infectious diseases: 3,703
  • Year to date:
    • Site-wide: 93,417
  • Since beginning of last month:
    • Site-wide: 103,418

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide